SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

27.82 5.06

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.6

Max

28.24

Põhinäitajad
By Trading Economics
Sissetulek	-13M -19M
Müük	-24M 3M
Kasumimarginaal	-618.236
Töötajad	103
EBITDA	-14M -13M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+28.98% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	20. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-50M 1.3B
Eelmine avamishind	22.76
Eelmine sulgemishind	27.82

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. apr 2026, 23:36 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14. apr 2026, 23:24 UTC

Kuumad aktsiad

Stocks to Watch: Gloo, Broadcom, GitLab

14. apr 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14. apr 2026, 21:32 UTC

Suurimad hinnamuutused turgudel

GitLab Shares Rise on Expanded Google Cloud Collaboration

14. apr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14. apr 2026, 22:54 UTC

Tulu

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14. apr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14. apr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14. apr 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

14. apr 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 20:32 UTC

Kuumad aktsiad

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14. apr 2026, 19:59 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 19:38 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14. apr 2026, 19:21 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14. apr 2026, 19:09 UTC

Omandamised, ülevõtmised, äriostud

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14. apr 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. apr 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

28.98% tõus

12 kuu keskmine prognoos

Keskmine 34 EUR 28.98%

Kõrge 34 EUR

Madal 34 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.